00:00Eli Lilly is making a bold move agreeing to acquire Colonia Therapeutics in a deal worth
00:05up to $7 billion, with billions tied to future milestones and a planned close in late 2026.
00:12At the heart of the deal, a cutting-edge approach that reprograms a patient's own immune cells
00:18inside the body, potentially transforming cancer care with a single IV treatment.
00:23Unlike today's complex lab-based CAR-T therapies, Colonia's in vivo technology could dramatically
00:30simplify treatment while expanding access beyond specialized centers.
00:35The high-stakes push comes as rivals like Johnson & Johnson and Gilead Sciences pour billions
00:40into similar breakthroughs, signaling a fierce race to dominate the future of cancer immunotherapy.
Comments